Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published before final editing as: Psychol Med. 2020 Oct 20:1–11. doi: 10.1017/S0033291720003797

Table 3.

Coverage for major depressive disorder by country income level

Coverage HICs LMICs Significance test
Numerator Denominator % (SE) % (SE) F (p-value)




Contact coverage People with 12-month MDD
(HICs:n=1,991;LMICs:n=1,350)
52.0 (1.5) 26.5 (1.3) 145.46* (<.001)
Any psychotropic medication People with contact coverage
(HICs:n=1,043;LMICs:n=355)
72.9 (2.2) 57.4 (2.9) 17.99* (<.001)
Antidepressants 48.6 (2.2) 35.0 (3.6) 9.75* (0.002)
Adequate medication control 39.1 (2.0) 35.8 (3.4) 0.70 (0.40)
Adequate pharmacotherapy 27.6 (1.7) 22.3 (3.3) 1.67 (0.20)
Any psychotherapy 38.8 (1.7) 39.2 (3.6) 0.01 (0.93)
Adequate psychotherapy 33.2 (1.7) 30.2 (3.4) 0.57 (0.45)
Adequate combination 23.6 (1.7) 21.7 (3.2) 0.19 (0.66)

Abbreviations: HICs, high income countries; LMICS, low or middle income countries; SE, standard error; MDD, major depressive disorder.

*

Significant at the .05 level, two-sided test

Adequate pharmacotherapy: taking an antidepressant with adequate medication control by any physician and adequate adherence; or taking any non-antidepressant psychotropic with adequate medication control by a psychiatrist and adequate patient adherence..